Manmeet Ahluwalia: The safety and feasibility of an oral drug called Terameprocol
Manmeet Ahluwalia, Chief of Medical Oncology, Deputy Director and Chief Scientific Officer of Miami Cancer Institute at Baptist Health South Florida, shared his recent article on LinkedIn, commenting :
“Elated to see another clinical trial publication through the NCI Adult Brain Tumor Consortium (ABTC), out now in Cell Reports Medicine Cell Press.
Patients with brain tumors particularly recurrent high-grade gliomas (rHGGs) continue to have a dismal prognosis, warranting investigation of novel therapies. This work is a culmination of a decade worth of collaborations with with Michelle Rudek, Ahmad Ozair, Lieberman Frank, Arati Desai, Glenn Lesser, David Peereboom, Holdhoff Matthias, Burt Nabors, Patrick Wen and Stuart Grossman, we were able to conduct and report a multicenter, phase 1 trial called GATOR investigated the safety and feasibility of an oral drug called Terameprocol (ABTC-1401). This is a unique transcriptional inhibitor of sp1-regulated proteins. While the oral drug was well-tolerated, we encountered challenges with systemic exposure. Our findings warrant trials where approaches providing sustained high levels of transcriptional inhibitors are utilized, to better exploit their therapeutic potential.”
Authors: Ahmad Ozair, Michelle Rudek, Xiaobu Ye, Matthias Holdhoff, Frank S. Lieberman, Anna F. Piotrowski, Burt Nabors, Arati Desai, Glenn Lesser, Ru Chih Huang, Steve Glenn, Atulya A. Khosla, David M. Peereboom, Patrick Y. Wen, Stuart A. Grossman.
